The effect of methylprednisolon plus mitoxantrone in the treatment of progressive multiple sclerosis
Not Applicable
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT201012245393N1
- Lead Sponsor
- Shahid Sadooghi University of Medical Sciences and Health Services
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
patients with progressive multiple sclerosis, Informed consent, age between 20-50 year
Exclusion criteria: HIV+ patients, cancer, heart failure, immunodeficiency patients, patients with neutrophil count less than 1500
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expanded Disability Status Scale. Timepoint: 6 months after the beginning of study. Method of measurement: by a checlkist, standard criteria.;Muscular power after treatment. Timepoint: 6 months after the beginning of study. Method of measurement: physical examination.;Cerebellum symptoms. Timepoint: 6 months after the beginning of study. Method of measurement: physical examination.;MRI findings (number of lesions) after treatment. Timepoint: 6 months after the beginning of study. Method of measurement: MRI.;Cranial nerves involvement. Timepoint: 6 months after the beginning of study. Method of measurement: physical examination.
- Secondary Outcome Measures
Name Time Method Heartburn. Timepoint: 6 months after the beginning of study. Method of measurement: ask from patients.;Vomitting. Timepoint: 6 months after the beginning of study. Method of measurement: ask from patients.;Anorexia. Timepoint: 6 months after the beginning of study. Method of measurement: ask from patients.;Hair loss. Timepoint: 6 months after the beginning of study. Method of measurement: ask from patients.;Leukopenia. Timepoint: 6 months after the beginning of study. Method of measurement: through hematologic test CBC.